Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL504722 | 0.91 | — | — | |
| SCHEMBL504753 | 0.89 | ACHE (0.43) | ACHE | |
| SCHEMBL2871115 | 0.87 | ACHE (0.45) | ACHE | |
| SCHEMBL504376 | 0.86 | ACHE (0.44) | ACHE | |
| SCHEMBL503674 | 0.86 | AGTR1 (0.44) | ACHE | |
| SCHEMBL504006 | 0.86 | APLNR (0.43) | ACHE | |
| SCHEMBL1889595 | 0.85 | ACHE (0.43) | ACHE | |
| SCHEMBL1889040 | 0.85 | ACHE (0.43) | ACHE | |
| SCHEMBL504351 | 0.85 | ACHE (0.41) | ACHE | |
| SCHEMBL504366 | 0.84 | ACHE (0.40) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664226-B2 | Compound having 3-heteroarylpyrimidin-4-(3H)-one structure and pharmaceutical preparation containing same | KOWA COMPANY, LTD. (JP) | 2014-03-04 | — | — | US | disclosed |
| EP-2420501-A1 | NOVEL COMPOUND HAVING 3-HETEROARYLPYRIMIDIN-4-(3H)-ONE STRUCTURE AND PHARMACEUTICAL PREPARATION CONTAINING SAME | Kowa Company, Ltd. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120028983-A1 | NOVEL COMPOUND HAVING 3-HETEROARYLPYRIMIDIN-4-(3H)-ONE STRUCTURE AND PHARMACEUTICAL PREPARATION CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028983-A1 | NOVEL COMPOUND HAVING 3-HETEROARYLPYRIMIDIN-4-(3H)-ONE STRUCTURE AND PHARMACEUTICAL PREPARATION CONTAINING SAME | AGTR2, AGTR1, GPR119 | ACHE 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.